(Oslo, May 6th) Aker BioMarine has entered into a new supply contract for Lysoveta, its novel brain health ingredient.
Aker BioMarine has secured a new supply contract for Lysoveta, its novel brain health ingredient. The contract is valued at approximately USD 4 million in the first year of the contract, with expected growth in 2027. Gross margin on Lysoveta is significantly higher than for Superba Krill Oil.
"This is exciting news for Lysoveta, a novel ingredient we have worked on commercializing over the past years. We believe the potential for Lysoveta is significant, and we are pleased to see this commercial progress.", said Matts Johansen, CEO of Aker BioMarine.
New science backs Lysoveta's brain health potential
The contract follows closely on a new preclinical study demonstrating that Lysoveta delivers the essential fatty acids EPA and DHA across the brain's protective barriers. Lysoveta contains EPA, DHA and choline in the form of lysophosphatidylcholine, the molecular form the brain naturally recognizes and actively transports via the MFSD2A pathway, enabling targeted delivery to brain tissue.
The study found significant enrichment of EPA and DHA in brain tissue. In mice carrying the APOE4 gene, the strongest known genetic risk factor for late-onset Alzheimer's disease, shifts in DHA-related metabolites indicate that Lysoveta activated relevant pathways in the brain, underscoring the importance of genotype-specific nutritional approaches.
"Our results show that Lysoveta can enrich brain-related tissues with EPA and DHA, supporting its potential as a targeted nutritional strategy for brain health. The distinct response observed in APOE4 further underscores the importance of genotype-specific approaches." Said Dr. Mélanie Plourde, Université de Sherbrooke.
From lab to global recognition
Lysoveta was introduced in November 2020 as the world's first commercially available EPA and DHA in lysophosphatidylcholine form. The ingredient is the result of more than seven years of R&D, built on the discovery that LPC is the primary molecule the brain uses to transport DHA across the blood-brain barrier. Lysoveta holds New Dietary Ingredient status in the US, with regulatory processes ongoing in Europe, China and Australia, and is backed by 40 patents across 16 countries. In 2025, it was named Innovation Winner at the Complementary Medicines Australia Industry Awards. A study published in April 2026 confirmed significant enrichment of EPA and DHA in brain tissue, including in models carrying the APOE4 gene, the strongest known genetic risk factor for late-onset Alzheimer's disease.
About Lysoveta
Lysoveta is a krill-derived brain health ingredient from Aker BioMarine, developed through extensive research. It delivers EPA and DHA in lysophosphatidylcholine form — the molecular structure the brain naturally recognizes and transports across its barriers via the MFSD2A pathway. Introduced in November 2020 as the world's first commercially available EPA/DHA in lysophosphatidylcholine form, Lysoveta is intended for use in science-based nutrition solutions targeting brain health and healthy aging.